CN106667953A - Apremilast soft capsule preparation and preparation process thereof - Google Patents
Apremilast soft capsule preparation and preparation process thereof Download PDFInfo
- Publication number
- CN106667953A CN106667953A CN201710077353.5A CN201710077353A CN106667953A CN 106667953 A CN106667953 A CN 106667953A CN 201710077353 A CN201710077353 A CN 201710077353A CN 106667953 A CN106667953 A CN 106667953A
- Authority
- CN
- China
- Prior art keywords
- soft capsule
- apremilast
- gelatin
- content
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses an apremilast soft capsule preparation. The apremilast soft capsule preparation comprises a soft capsule and a content, wherein a formula of the content is as follows: 0.5g to 1.5g of apremilast raw material; 200g to 250g of caprylic/capric polyethylene glycol glyceride; 30g to 60g of polyglycerin oleate; 50g to 100g of medium chain triglyceride; and 0.02g to 0.05g of 2,6-ditertbutyl-4 methylphenol. The apremilast soft capsule provided by the invention can remarkably improve accumulated dissolution rate of dissolution in 5 minutes, and can improve the dissolution efficiency of a main drug in a preliminary period of time; and the apremilast soft capsule has good stability and good product appearance quality.
Description
Technical field
The present invention relates to technical field of medicine, and in particular to a kind of Apremilast soft capsule preparation and its preparation work
Skill.
Background technology
Apremilast（apremilast）It is the PDE4 inhibitor of Celgene research and development, current clinical development rheumatoid is closed
Multiple indications such as section inflammation, psoriatic arthritis, behcets disease, ulcerative colitiss.The FDA of on March 21st, 2014 approvals first
Individual indication -- activities of adults psoriatic arthritis（psoriatic arthritis, PsA）.Trade name：OTEZLA®（
FDA requires that manufacturer will assess exposure of the medicine to pregnant female by a pregnant registration studies imitates as after listing
Should.）The safety of three clinical laboratory evaluations Apremilast treatment PsA and effectiveness, Apremilast group and placebo group
ACR20 response rates are respectively 32-41%, 18-19%.Apremilast is the oral antirheumatic of a brand-new mechanism of action, with
At present clinical conventional anti-TNF monoclonal antibodies are had any different, and EvaluatePharma predicts that 2018 annual sales amounts are 12.19 hundred million dollars.
The estimated highest of the sales volume of Apremilast is up to 2,000,000,000 dollars.Main indication of expanding is rheumatoid arthritis and specificity skin
It is scorching.On July 14th, 2014, Celgene companies announced the clinical failure of the mandatory phase of myelitis 3, and the plan of next step research worker will be controlled
The treatment cycle extended to 52 weeks to observe curative effect of medication by present 16 weeks.
Apremilast has the advantage that compared with similar：It can suppress various proinflammatory mediators（PDE-4、TNF-α、IL-
2nd, interferon r, leukotriene, NO synzyme）Generation and play antiinflammatory action；PDE 4（PDE4）Selective depression
Agent, in addition to approval is for psoriasis arthropathica, in September, 2014 FDA is ratified to be treated for the middle severe of phototherapy or constitutional treatment
Plaque psoriasis patient.Be it is first be also uniquely to be approved the PDE4 inhibitor for treating plaque psoriasis；Clinical trial
Show, OTEZLA can reduce in severe plaque psoriasis patient erythema, thicken and desquamation.Clinical trial proves Apremilast
Better tolerance, untoward reaction is less, and Otezla treatment groups compare with placebo in clinical trial, and patient shows PsA signs and disease
The improvement of shape, including tenderness, arthroncuss and body function；Other indications are doing clinic, such as rheumatic arthritis, pressure
Property myelitis, behcets disease, ulcerative colitiss etc..Market potential is larger.
The content of the invention
It is an object of the invention to provide a kind of Apremilast soft capsule preparation.
It is, up to above-mentioned purpose, a kind of Apremilast soft capsule preparation to be provided in one embodiment of the present of invention, including it is soft
Capsule and content, content prescription is：
Apremilast raw material 0.5g ~ 1.5g；
Caprylocaproyl Macrogolglycerides 200g~250g；
Polyglycerol acrylate 30g~60g；
Medium chain Triglyceride 50g~100g；
DBPC 2,6 ditertiary butyl p cresol 0.02g~0.05g.
In one preferred version of the present invention, content prescription is：
Apremilast raw material 1g；
Caprylocaproyl Macrogolglycerides 220g~240g；
Polyglycerol acrylate 40g~50g；
Medium chain Triglyceride 60g~90g；
DBPC 2,6 ditertiary butyl p cresol 0.03g~0.04g.
In one preferred version of the present invention, content prescription is：
Apremilast raw material 1.5g；
Caprylocaproyl Macrogolglycerides 220g；
Polyglycerol acrylate 45g；
Medium chain Triglyceride 75g；
DBPC 2,6 ditertiary butyl p cresol 0.035g.
In one preferred version of the present invention, content prescription is：
Apremilast raw material 1.5g；
Caprylocaproyl Macrogolglycerides 235g；
Polyglycerol acrylate 48g；
Medium chain Triglyceride 78g；
DBPC 2,6 ditertiary butyl p cresol 0.04g.
In one preferred version of the present invention, the prescription of soft capsule is：
Gelatin 140mg~180mg；
Glycerol 70mg~100mg；
Yellow ferric oxide 0.1mg~0.4mg；
Titanium dioxide 1mg~3mg.
In one preferred version of the present invention, the prescription of soft capsule is：
Gelatin 160mg；
Glycerol 80mg；
Yellow ferric oxide 0.29mg；
Titanium dioxide 2mg.
In one preferred version of the present invention, the prescription of soft capsule is：
Gelatin 150mg；
Glycerol 90mg；
Yellow ferric oxide 0.35mg；
Titanium dioxide 2.5mg.
Another object of the present invention is to improve a kind of technique for preparing Apremilast soft capsule preparation, including following step
Suddenly：
(1) content is prepared：Caprylocaproyl Macrogolglycerides, polyglycerol acrylate and the medium chain triglyceride three for taking recipe quantity is sour
Ester stirs, and the Apremilast crude drug and 2,6 ditertiary butyl p cresol of recipe quantity are added after intensification, continues to stir
After be down to room temperature, obtain content；
(2) soft capsule is prepared：It is uniformly mixed in glycerol addition water the being placed in glue tank for taking recipe quantity, is subsequently adding what is sieved
Titanium dioxide and yellow ferric oxide mix homogeneously, are subsequently adding gelatin and are heated to 60 DEG C~80 DEG C；Continue to stir to gelatin
It is completely dissolved；Vacuum is opened after Gelatin makes glue deaerate, and degassing is lowered the temperature after finishing；
(3) pill：Inside Contents Fill to soft capsule, will shape, be dried using soft capsule, obtain pastille soft capsule.
In one preferred version of the present invention, Caprylocaproyl Macrogolglycerides, polyglycerol acrylate and medium chain triglyceride
Three acid esters stir, and Apremilast crude drug and 2,6 ditertiary butyl p cresol are added after being warming up to 40 DEG C.
In one preferred version of the present invention, the capsule severe edema due to hypofunction of the spleen of pastille soft capsule is divided into 8%~12%.
The polyglycerol acrylate of the present invention is bought in the product polyglycerol acrylate of the good method lion of France.
In sum, the present invention has advantages below：
The Apremilast soft capsule of the present invention, can significantly improve the dissolution accumulation dissolution of 5 minutes, improve principal agent in the front time
The dissolution efficiency of section；With good stability, product appearance quality is good.Secondly the present invention is selected by the optimization to component
Select, reduce harmful effect of the Propylene Glycol to principal agent migration, stability, dissolution and bioavailability.
Specific embodiment
Embodiment 1
Apremilast soft capsule preparation content prescription：
Apremilast raw material 0.5g；Caprylocaproyl Macrogolglycerides 220g；
Polyglycerol acrylate 45g；Medium chain Triglyceride 75g；
DBPC 2,6 ditertiary butyl p cresol 0.035g.
Soft capsule prescription：
Gelatin 160mg；Glycerol 80mg；
Yellow ferric oxide 0.29mg；Titanium dioxide 2mg.
Preparation method：
(1) content is prepared：Caprylocaproyl Macrogolglycerides, polyglycerol acrylate and the medium chain triglyceride three for taking recipe quantity is sour
Ester stirs, and is warmed up to after 40 DEG C and adds the Apremilast crude drug and 2,6 ditertiary butyl p cresol of recipe quantity, continues to stir
1h is mixed to room temperature is down to after uniform, content is obtained；
(2) soft capsule is prepared：It is uniformly mixed in glycerol addition water the being placed in glue tank for taking recipe quantity, was subsequently adding 80 mesh
The titanium dioxide and yellow ferric oxide mix homogeneously of sieve, is subsequently adding gelatin and is heated to 70 DEG C；Continue to stir 1h to gelatin
Stop stirring after being completely dissolved；Vacuum is opened after Gelatin keeps vacuum bag -0.09Mpa to make glue degassing 30min, has deaerated
Lower the temperature 60 DEG C after finishing, stand standby after 24h；
(3) pill：Encapsulating machine is heated after being debugged to sprinkler body；Adjustment revolving die pressure, is advisable with just extruding soft gelatin capsule,
Pressure is avoided to cross conference mold damage.Loading amount regulation is carried out, sampling detection extrudes crack quality, outward appearance, the content weight of soft gelatin capsule,
Adjust in time, till meeting the requirements；Cylinder is opened, by the soft gelatin capsule sizing of compacting；The soft gelatin capsule of compacting is determined in cylinder
Take out after type, be placed in 30 DEG C, be dried in the environment of below RH50%, and the sampling detection capsule severe edema due to hypofunction of the spleen point at any time, when the capsule severe edema due to hypofunction of the spleen point exists
When 8%~12%, stop drying.
Embodiment 2
Apremilast soft capsule preparation content prescription：
Apremilast raw material 1g；Caprylocaproyl Macrogolglycerides 225g；
Polyglycerol acrylate 50g；Medium chain Triglyceride 72g；
DBPC 2,6 ditertiary butyl p cresol 0.038g.
Soft capsule prescription：
Gelatin 160mg；Glycerol 80mg；
Yellow ferric oxide 0.25mg；Titanium dioxide 2.2mg.
Preparation method：
(1) content is prepared：Caprylocaproyl Macrogolglycerides, polyglycerol acrylate and the medium chain triglyceride three for taking recipe quantity is sour
Ester stirs, and is warmed up to after 40 DEG C and adds the Apremilast crude drug and 2,6 ditertiary butyl p cresol of recipe quantity, continues to stir
1h is mixed to room temperature is down to after uniform, content is obtained；
(2) soft capsule is prepared：It is uniformly mixed in glycerol addition water the being placed in glue tank for taking recipe quantity, was subsequently adding 80 mesh
The titanium dioxide and yellow ferric oxide mix homogeneously of sieve, is subsequently adding gelatin and is heated to 70 DEG C；Continue to stir 1h to gelatin
Stop stirring after being completely dissolved；Vacuum is opened after Gelatin keeps vacuum bag -0.09Mpa to make glue degassing 30min, has deaerated
Lower the temperature 60 DEG C after finishing, stand standby after 24h；
(3) pill：Encapsulating machine is heated after being debugged to sprinkler body；Adjustment revolving die pressure, is advisable with just extruding soft gelatin capsule,
Pressure is avoided to cross conference mold damage.Loading amount regulation is carried out, sampling detection extrudes crack quality, outward appearance, the content weight of soft gelatin capsule,
Adjust in time, till meeting the requirements；Cylinder is opened, by the soft gelatin capsule sizing of compacting；The soft gelatin capsule of compacting is determined in cylinder
Take out after type, be placed in 30 DEG C, be dried in the environment of below RH50%, and the sampling detection capsule severe edema due to hypofunction of the spleen point at any time, when the capsule severe edema due to hypofunction of the spleen point exists
When 8%~12%, stop drying.
Embodiment 3
Apremilast soft capsule preparation content prescription：
Apremilast raw material 1.5g；Caprylocaproyl Macrogolglycerides 220g；
Polyglycerol acrylate 45g；Medium chain Triglyceride 75g；
Soft capsule prescription：
Gelatin 161mg；Glycerol 85mg；
Yellow ferric oxide 0.27mg；Titanium dioxide 2mg.
Preparation method：
(1) content is prepared：Caprylocaproyl Macrogolglycerides, polyglycerol acrylate and the medium chain triglyceride three for taking recipe quantity is sour
Ester stirs, and the Apremilast crude drug that recipe quantity is added after being warmed up to 40 DEG C continues to stir 1h to being down to room temperature after uniform,
Obtain content；
(2) soft capsule is prepared：It is uniformly mixed in glycerol addition water the being placed in glue tank for taking recipe quantity, was subsequently adding 80 mesh
The titanium dioxide and yellow ferric oxide mix homogeneously of sieve, is subsequently adding gelatin and is heated to 70 DEG C；Continue to stir 1h to gelatin
Stop stirring after being completely dissolved；Vacuum is opened after Gelatin keeps vacuum bag -0.09Mpa to make glue degassing 30min, has deaerated
Lower the temperature 60 DEG C after finishing, stand standby after 24h；
(3) pill：Encapsulating machine is heated after being debugged to sprinkler body, and control temperature is at 35 DEG C；Adjustment revolving die pressure, with firm
Extrude soft gelatin capsule well to be advisable, it is to avoid pressure crosses conference mold damage.Loading amount regulation is carried out, sampling detection extrudes the crack matter of soft gelatin capsule
Amount, outward appearance, content weight, adjust in time, till meeting the requirements；Cylinder is opened, by the soft gelatin capsule sizing of compacting；Will pressure
The soft gelatin capsule of system takes out after cylinder sizing, is placed in 30 DEG C, is dried in the environment of below RH50%, and the capsule severe edema due to hypofunction of the spleen of sampling detection at any time
Point, when the capsule severe edema due to hypofunction of the spleen point is 8%~12%, stop drying.
Embodiment 4
Apremilast soft capsule preparation content prescription：
Apremilast raw material 1.5g；Caprylocaproyl Macrogolglycerides 210g；
Polyglycerol acrylate 40g；Medium chain Triglyceride 70g；
Butylated hydroxyanisole BHA0.035g.
Soft capsule prescription：
Gelatin 160mg；Glycerol 85mg；
Yellow ferric oxide 0.28mg；Titanium dioxide 2mg.
Preparation method：
(1) content is prepared：Caprylocaproyl Macrogolglycerides, polyglycerol acrylate and the medium chain triglyceride three for taking recipe quantity is sour
Ester stirs, and is warmed up to after 40 DEG C and adds the Apremilast crude drug and Butylated hydroxyanisole BHA of recipe quantity to continue to stir
1h obtains content to room temperature is down to after uniform；
(2) soft capsule is prepared：It is uniformly mixed in glycerol addition water the being placed in glue tank for taking recipe quantity, was subsequently adding 80 mesh
The titanium dioxide and yellow ferric oxide mix homogeneously of sieve, is subsequently adding gelatin and is heated to 70 DEG C；Continue to stir 1h to gelatin
Stop stirring after being completely dissolved；Vacuum is opened after Gelatin keeps vacuum bag -0.09Mpa to make glue degassing 30min, has deaerated
Lower the temperature 60 DEG C after finishing, stand standby after 24h；
(3) pill：Encapsulating machine is heated after being debugged to sprinkler body；Adjustment revolving die pressure, is advisable with just extruding soft gelatin capsule,
Pressure is avoided to cross conference mold damage.Loading amount regulation is carried out, sampling detection extrudes crack quality, outward appearance, the content weight of soft gelatin capsule,
Adjust in time, till meeting the requirements；Cylinder is opened, by the soft gelatin capsule sizing of compacting；The soft gelatin capsule of compacting is determined in cylinder
Take out after type, be placed in 30 DEG C, be dried in the environment of below RH50%, and the sampling detection capsule severe edema due to hypofunction of the spleen point at any time, when the capsule severe edema due to hypofunction of the spleen point exists
When 8%~12%, stop drying.
Embodiment 5
Apremilast soft capsule preparation content prescription：
Apremilast raw material 1g；Caprylocaproyl Macrogolglycerides 225g；
Polyglycerol acrylate 46g；Medium chain Triglyceride 75g；
Sodium pyrosulfite 0.036g.
Soft capsule prescription：
Gelatin 160mg；Glycerol 85mg；
Yellow ferric oxide 0.28mg；Titanium dioxide 2mg.
Preparation method：
(1) content is prepared：Caprylocaproyl Macrogolglycerides, polyglycerol acrylate and the medium chain triglyceride three for taking recipe quantity is sour
Ester stirs, and is warmed up to after 40 DEG C and adds the Apremilast crude drug and sodium pyrosulfite of recipe quantity, continues to stir 1h to equal
Room temperature is down to after even, content is obtained；
(2) soft capsule is prepared：It is uniformly mixed in glycerol addition water the being placed in glue tank for taking recipe quantity, was subsequently adding 80 mesh
The titanium dioxide and yellow ferric oxide mix homogeneously of sieve, is subsequently adding gelatin and is heated to 70 DEG C；Continue to stir 1h to gelatin
Stop stirring after being completely dissolved；Vacuum is opened after Gelatin keeps vacuum bag -0.09Mpa to make glue degassing 30min, has deaerated
Lower the temperature 60 DEG C after finishing, stand standby after 24h；
(3) pill：Encapsulating machine is heated after being debugged to sprinkler body, and control temperature is at 35 DEG C；Adjustment revolving die pressure, with firm
Extrude soft gelatin capsule well to be advisable, it is to avoid pressure crosses conference mold damage.Loading amount regulation is carried out, sampling detection extrudes the crack matter of soft gelatin capsule
Amount, outward appearance, content weight, adjust in time, till meeting the requirements；Cylinder is opened, by the soft gelatin capsule sizing of compacting；Will pressure
The soft gelatin capsule of system takes out after cylinder sizing, is placed in 30 DEG C, is dried in the environment of below RH50%, and the capsule severe edema due to hypofunction of the spleen of sampling detection at any time
Point, when the capsule severe edema due to hypofunction of the spleen point is 8%~12%, stop drying.
Claims (10)
1. a kind of Apremilast soft capsule preparation, including soft capsule and content, it is characterised in that：The content prescription is：
Apremilast raw material 0.5g ~ 1.5 g；
Caprylocaproyl Macrogolglycerides 200g ~ 250g；
Polyglycerol acrylate 30g ~ 60g；
Medium chain Triglyceride 50g ~ 100g；
DBPC 2,6 ditertiary butyl p cresol 0.02g ~ 0.05g.
2. soft capsule preparation as claimed in claim 1, it is characterised in that：The content prescription is：
Apremilast raw material 1g；
Caprylocaproyl Macrogolglycerides 220g ~ 240g；
Polyglycerol acrylate 40g ~ 50g；
Medium chain Triglyceride 60g ~ 90g；
DBPC 2,6 ditertiary butyl p cresol 0.03g ~ 0.04g.
3. soft capsule preparation as claimed in claim 1, it is characterised in that：The content prescription is：
Apremilast raw material 1.5g；
Caprylocaproyl Macrogolglycerides 220g；
Polyglycerol acrylate 45g；
Medium chain Triglyceride 75g；
DBPC 2,6 ditertiary butyl p cresol 0.035g.
4. soft capsule preparation as claimed in claim 1, it is characterised in that：The content prescription is：
Apremilast raw material 1.5g；
Caprylocaproyl Macrogolglycerides 235g；
Polyglycerol acrylate 48g；
Medium chain Triglyceride 78g；
DBPC 2,6 ditertiary butyl p cresol 0.04g.
5. soft capsule preparation as claimed in claim 1, it is characterised in that the prescription of the soft capsule is：
Gelatin 140mg ~ 180mg；
Glycerol 70mg ~ 100mg；
Yellow ferric oxide 0.1mg ~ 0.4mg；
Titanium dioxide 1mg ~ 3mg.
6. soft capsule preparation as claimed in claim 5, it is characterised in that the prescription of the soft capsule is：
Gelatin 160mg；
Glycerol 80mg；
Yellow ferric oxide 0.29mg；
Titanium dioxide 2mg.
7. soft capsule preparation as claimed in claim 5, it is characterised in that the prescription of the soft capsule is：
Gelatin 152mg；
Glycerol 92mg；
Yellow ferric oxide 0.35mg；
Titanium dioxide 2.5mg.
8. the technique for preparing arbitrary Apremilast soft capsule preparation in claim 1 ~ 7, comprises the following steps：
（1）Prepare content：Caprylocaproyl Macrogolglycerides, polyglycerol acrylate and the medium chain triglyceride three for taking recipe quantity is sour
Ester stirs, and the Apremilast crude drug and 2,6 ditertiary butyl p cresol of recipe quantity are added after intensification, continues to stir
After be down to room temperature, obtain content；
（2）Prepare soft capsule：It is uniformly mixed in glycerol addition water the being placed in glue tank for taking recipe quantity, is subsequently adding what is sieved
Titanium dioxide and yellow ferric oxide mix homogeneously, are subsequently adding gelatin and are heated to 60 DEG C ~ 80 DEG C；Continue to stir complete to gelatin
CL；Vacuum is opened after Gelatin makes glue deaerate, and degassing is lowered the temperature after finishing；
（3）Pill：Inside Contents Fill to soft capsule, will shape, be dried using soft capsule, obtain pastille soft capsule.
9. preparation technology as claimed in claim 8, it is characterised in that：The Caprylocaproyl Macrogolglycerides, polyglycereol
Oleate and Medium chain Triglyceride stir, and Apremilast crude drug and 2,6- di-t-butyl pair are added after being warming up to 40 DEG C
Cresol.
10. preparation technology as claimed in claim 8, it is characterised in that：The capsule severe edema due to hypofunction of the spleen of the pastille soft capsule is divided into 8% ~ 12%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710077353.5A CN106667953A (en) | 2017-02-14 | 2017-02-14 | Apremilast soft capsule preparation and preparation process thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710077353.5A CN106667953A (en) | 2017-02-14 | 2017-02-14 | Apremilast soft capsule preparation and preparation process thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106667953A true CN106667953A (en) | 2017-05-17 |
Family
ID=58861916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710077353.5A Pending CN106667953A (en) | 2017-02-14 | 2017-02-14 | Apremilast soft capsule preparation and preparation process thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106667953A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107982267A (en) * | 2017-12-28 | 2018-05-04 | 佛山市腾瑞医药科技有限公司 | A kind of razaxaban soft capsule preparation and its preparation process |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104546831A (en) * | 2014-12-30 | 2015-04-29 | 杭州新博思生物医药有限公司 | Medicine composition containing apremilast |
| CN105395517A (en) * | 2015-12-11 | 2016-03-16 | 成都华宇制药有限公司 | Dutasteride soft capsule preparation and preparation process thereof |
-
2017
- 2017-02-14 CN CN201710077353.5A patent/CN106667953A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104546831A (en) * | 2014-12-30 | 2015-04-29 | 杭州新博思生物医药有限公司 | Medicine composition containing apremilast |
| CN105395517A (en) * | 2015-12-11 | 2016-03-16 | 成都华宇制药有限公司 | Dutasteride soft capsule preparation and preparation process thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107982267A (en) * | 2017-12-28 | 2018-05-04 | 佛山市腾瑞医药科技有限公司 | A kind of razaxaban soft capsule preparation and its preparation process |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105395517B (en) | A kind of dutasteride's soft capsule preparation and its preparation technology | |
| CN110891552B (en) | Enteric hard capsule | |
| JP2016523846A5 (en) | ||
| JP2015155480A (en) | Fumaric acid derivative-containing medicament for treating cardiac failure and asthma | |
| JP2010534644A (en) | Pharmaceutical composition and method for producing the same | |
| CN103124498A (en) | Oral formulations of bipolar trans carotenoids | |
| CN104940156A (en) | Epalrestat enteric-coated and sustained-release tablets and preparation method thereof | |
| CN107173790A (en) | A kind of preparation method of potato vermicelli | |
| JP2020040970A (en) | Pharmaceutical composition | |
| CN105878208B (en) | A kind of starch base plant medicinal hard capsule forming agent and its application | |
| CN106667953A (en) | Apremilast soft capsule preparation and preparation process thereof | |
| CN105106168A (en) | Esomeprazole magnesium enteric capsules and preparation method thereof | |
| CN105326801B (en) | A kind of preparing process and application method of esomeprazole enteric coating liquid | |
| CN103908441A (en) | Enteric-coated soft capsule of Omega-3 aliphatic acid and its derivative and preparation method of the enteric-coated soft capsule | |
| CN101708172A (en) | Enteric hollow capsule | |
| CN100537593C (en) | Glycyrrhizic acid double salt and preparation thereof | |
| JP6440294B2 (en) | Telmisartan-containing film-coated tablets | |
| CN107982240B (en) | Potassium sodium dehydroandroan drographolide succinate enteric coated granules capable of being accurately dissolved out and preparation method thereof | |
| CN101209247B (en) | Preparation of colon-targeted preparation | |
| CN106667954A (en) | Diacerein soft capsule preparation and preparation process thereof | |
| CN102771793A (en) | Multivitamin preparation and preparation method thereof | |
| CN107898770A (en) | A kind of Zaltoprofen soft capsule preparation and its preparation process | |
| CN107998100A (en) | A kind of Febustat soft capsule preparation and its preparation process | |
| CN106822048A (en) | A kind of microporous barrier controlled release coat Apremilast micropill and preparation method thereof | |
| CN106580913A (en) | Trelagliptin succinate soft capsule preparation and preparation process thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170517 |